Welcome to our dedicated page for Genprex news (Ticker: GNPX), a resource for investors and traders seeking the latest updates and insights on Genprex stock.
Genprex Inc (NASDAQ: GNPX) is a clinical-stage biotechnology company pioneering gene therapies for cancer and diabetes through its non-viral Oncoprex Delivery System. This dedicated news hub provides investors and researchers with timely updates on clinical developments, regulatory milestones, and strategic partnerships.
Access essential updates including Reqorsa Gene Therapy trial progress, FDA designations for lung cancer treatments, and advancements in diabetes program GPX-002. Our curated collection features press releases on scientific collaborations, financial disclosures, and therapeutic innovation breakthroughs.
Key focus areas include tumor suppressor gene research, combination therapy trials, and novel approaches to pancreatic cell transformation. Bookmark this page for verified updates about Genprex's pipeline developments and industry recognition in the oncology and diabetes therapeutic spaces.
Genprex announced the first patient dosing in its Phase 1 Acclaim-3 clinical study of Reqorsa Immunogene Therapy in combination with Tecentriq to treat extensive-stage small cell lung cancer (ES-SCLC). This trial, which aims to determine the maximum tolerated dose for a Phase 2 expansion expected in the second half of 2024, is supported by FDA Orphan Drug and Fast Track designations. Genprex highlighted the poor prognosis of ES-SCLC and the benefits of current treatments, emphasizing the potential of their therapy. Positive outcomes from the Phase 1 Acclaim-1 study in non-small cell lung cancer have enabled an accelerated timeline for Acclaim-3.
Genprex, a clinical-stage gene therapy company, announced the appointment of Jose A. Moreno Toscano as Chairman of the Board following the passing of the previous Chairman, Rodney Varner. Mr. Moreno Toscano brings over 20 years of experience in the pharmaceutical and biotechnology industries, focusing on revenue growth, market expansion, and organizational development.
Genprex, a clinical-stage gene therapy company, announced the passing of its co-founder and CEO, Rodney Varner, due to complications from cancer. Ryan Confer has been appointed as the new President and CEO. Under Varner's leadership, the company achieved significant milestones in developing therapies for cancer and diabetes. The company expresses its condolences to Varner's family and colleagues.
Genprex, Inc. (
FAQ
What is the current stock price of Genprex (GNPX)?
What is the market cap of Genprex (GNPX)?
